Nuformix PLC Announce Encouraging Results from Studies for their NXP002 Lung Fibrosis Treatment #NFX

StockBox

10.8K subscribers

ShareSubscribe

Mark Fairbairn speaks to Executive Director Dan Gooding about the treatment the company are developing for lung fibrosis and results of recent studies the company undertook. There is a significant need to improve the treatment options for lung fibrosis, as the condition is debilitating and severely affects patients' quality of life. The company's treatment aims to work in addition to the existing standards of care to enhance efficacy and potentially improve disease outcomes. The announcement of the treatment's extended duration of action is a transformative moment for the company and has the potential to change the landscape of IPF treatment.